Groundbreaking HostDx Tests
The Inflammatix HostDx diagnostics are powered by ‘reading’ the immune system instead of looking for a bug. Our immune system has developed targeted responses to different types of infections and other diseases over millions of years of evolution. We are initially launching HostDx Sepsis and HostDx Fever for better acute infection and sepsis diagnosis based on patent-pending biomarkers exclusively licensed from Stanford University.
Where Are We Now?
We are in the process of fitting our HostDx assays onto novel diagnostic instruments with ideal product-market fit. Then, we will execute clinical studies required for regulatory clearance across the globe.
Scour appropriate cohorts in public and private datasets (raw gene expression and clinical data) to identify optimal genes and develop algorithms
Apply locked algorithms on multiple independent (blinded) public and private data sets (also with raw gene expression and clinical data)
Develop assays (wet lab) based on locked set of genes and algorithms and onboard onto novel rapid point-of-care instrument
Validate assay locked on instrument in independent (blinded) and representative clinical studies
Attain regulatory clearance (e.g. CE, 510K) and launch HostDx tests to clinics and hospitals globally
Deep pipeline of novel, rapid HostDx™ tests
All new indications run on our <25 min POC platform